Comparative analysis of aldosterone and renin assays for primary aldosteronism screening.
Aldosterone
Chemiluminescent enzyme immunoassay
Liquid chromatography/mass spectrometry/mass spectrometry
Primary aldosteronism
Radioimmunoassay
Weak mineralocorticoid
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 10 2024
29 10 2024
Historique:
received:
04
08
2024
accepted:
07
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for plasma aldosterone concentration (PAC) assays has raised concerns over its impact on primary aldosteronism (PA) diagnosis. This study investigated the correlation between PAC and renin values using RIA, CLEIA, and liquid chromatography/mass spectrometry/mass spectrometry (LC-MS/MS), established cutoff values for PA diagnosis using the aldosterone-to-renin ratio (ARR) with PAC_CLEIA, and assessed the differences in PAC values by measuring weak mineralocorticoids (WMs). This retrospective study evaluated 312 serum PAC samples using RIA, CLEIA, and LC-MS/MS, and analyzed 315 plasma renin samples. Method correlations were assessed through Passing-Bablok regression. Receiver operating characteristic curves determined ARR cutoffs for PA diagnosis. WMs were quantified to evaluate their impact on ΔPAC (RIA-LC-MS/MS) through multiple regression analysis. PAC_CLEIA and PAC_LC-MS/MS values were highly correlated. ARRs derived from PAC_RIAs demonstrated more false positives and lower specificity than ARRs using PAC_CLEIA or PAC_LC-MS/MS. WMs significantly influenced ΔPAC in both the PA and non-PA groups. ARRs using PAC_CLEIA are valuable for determining PA cutoffs in clinical practice. The transition to PAC using CLEIA may enhance PA detection rates. WMs were found to interfere with PAC measurements in the RIA method, affecting outcomes.
Identifiants
pubmed: 39472614
doi: 10.1038/s41598-024-75645-1
pii: 10.1038/s41598-024-75645-1
doi:
Substances chimiques
Renin
EC 3.4.23.15
Aldosterone
4964P6T9RB
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
26040Subventions
Organisme : the Ministry of Education, Culture, Sports, Science and Technology
ID : 21H02974
Organisme : Fund for the Promotion of Joint International Research
ID : 19KK04071
Organisme : the Japan Society for the Promotion of Science KAKENHI
ID : JP19H03708
Informations de copyright
© 2024. The Author(s).
Références
Reincke, M. et al. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 9(12), 876–892 (2021).
doi: 10.1016/S2213-8587(21)00210-2
Ohno, Y. et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in Japan. Hypertension 71(3), 530–537 (2018).
doi: 10.1161/HYPERTENSIONAHA.117.10263
Yoshida, Y. & Shibata, H. Recent progress in the diagnosis and treatment of primary aldosteronism. Hypertens. Res. 46(7), 1738–1744 (2023).
doi: 10.1038/s41440-023-01288-w
Meng, X. et al. Evaluation of the saline infusion test and the captopril challenge test in Chinese patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 103(3), 853–860 (2018).
doi: 10.1210/jc.2017-01530
Buffolo, F. et al. Is primary aldosteronism still largely unrecognized?. Horm. Metab. Res. 49(12), 908–914 (2017).
doi: 10.1055/s-0043-119755
Scholl, U. I. et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat. Genet. 45(9), 1050–1054 (2013).
doi: 10.1038/ng.2695
Rossi, G. P. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J. Am. Coll. Cardiol. 48(11), 2293–2300 (2006).
doi: 10.1016/j.jacc.2006.07.059
Naruse, M. et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr. J. 69(4), 327–359 (2022).
doi: 10.1507/endocrj.EJ21-0508
Burrello, J. et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 75(4), 1025–1033 (2020).
doi: 10.1161/HYPERTENSIONAHA.119.14063
Mantero, F., Mattarello, M. J. & Albiger, N. M. Detecting and treating primary aldosteronism: Primary aldosteronism. Exp. Clin. Endocrinol. Diabetes 115(3), 171–174 (2007).
doi: 10.1055/s-2007-970409
Baudrand, R. et al. Continuum of renin-independent aldosteronism in normotension. Hypertension 69(5), 950–956 (2017).
doi: 10.1161/HYPERTENSIONAHA.116.08952
Nishikawa, T., Saito, J. & Omura, M. Prevalence of primary aldosteronism: Should we screen for primary aldosteronism before treating hypertensive patients with medication?. Endocr. J. 54(4), 487–495 (2007).
doi: 10.1507/endocrj.KR-105
Chen, S., Liu, H., Luo, P. & Yu, Y. Computed tomography combined with confirmatory tests for the diagnosis of aldosterone-producing adenoma. Endocr. J. 68(3), 299–306 (2021).
doi: 10.1507/endocrj.EJ20-0395
Naruse, M. et al. International multicenter survey on screening and confirmatory testing in primary aldosteronism. Eur. J. Endocrinol. 188(1), 125–134 (2023).
doi: 10.1093/ejendo/lvac002
Tamura, N. et al. Comparisons of plasma aldosterone and renin data between an automated chemiluminescent immunoanalyzer and conventional radioimmunoassays in the screening and diagnosis of primary aldosteronism. PLoS One 16(7), e0253807 (2021).
doi: 10.1371/journal.pone.0253807
Ito, T., Woo, J., Haning, R. & Horton, R. A radioimmunoassay for aldosterone in human peripheral plasma including a comparison of alternate techniques. J. Clin. Endocrinol. Metab. 34(1), 106–112 (1972).
doi: 10.1210/jcem-34-1-106
Umemura, S. et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens. Res. 42(9), 1235–1481 (2019).
doi: 10.1038/s41440-019-0284-9
Pizzolo, F. et al. Fully automated chemiluminescence vs RIA aldosterone assay in primary aldosteronism work-up. J. Hum. Hypertens. 31(12), 826–830 (2017).
doi: 10.1038/jhh.2017.62
Nishikawa, T. et al. Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood. Endocr. J. 63(12), 1065–1080 (2016).
doi: 10.1507/endocrj.EJ16-0304
Kobayashi, H. et al. Impact of a change to a novel chemiluminescent immunoassay for measuring plasma aldosterone on the diagnosis of primary aldosteronism. Endocr. J. 70(5), 489–500 (2023).
doi: 10.1507/endocrj.EJ22-0585
Teruyama, K., Naruse, M., Tsuiki, M. & Kobayashi, H. Novel chemiluminescent immunoassay to measure plasma aldosterone and plasma active renin concentrations for the diagnosis of primary aldosteronism. J. Hum. Hypertens. 36(1), 77–85 (2021).
doi: 10.1038/s41371-020-00465-5
Nishikawa, T. et al. Comparison and commutability study between standardized liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) and chemiluminescent enzyme immunoassay for aldosterone measurement in blood. Endocr. J. 69(1), 45–54 (2022).
doi: 10.1507/endocrj.EJ21-0278
Noh, J., Lee, C., Kim, J. H., Myung, S. W. & Choi, M. H. LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines. J. Lipid Res. 6, 100453 (2023).
doi: 10.1016/j.jlr.2023.100453
Ng, E. et al. Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism. J. Clin. Endocrinol. Metab. 108(1), 33–41 (2022).
doi: 10.1210/clinem/dgac568
Chen, F. et al. A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay for simultaneous quantification of aldosterone, renin activity, and angiotensin II in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1179, 122740 (2021).
doi: 10.1016/j.jchromb.2021.122740
Liu, Z., Jin, L., Zhou, W. & Zhang, C. The spectrum of plasma renin activity and hypertension diseases: Utility, outlook, and suggestions. J. Clin. Lab. Anal. 36(11), e24738 (2022).
doi: 10.1002/jcla.24738
Tan, X., Li, F., Wang, X. & Wang, Y. Quantitation and clinical evaluation of plasma aldosterone by ultra-performance liquid chromatography–mass spectrometry. J. Chromatogr. A 1609, 460456 (2020).
doi: 10.1016/j.chroma.2019.460456
Satoh, F. et al. New screening cutoff values for detection of aldosteronoma examined by LC-MS/MS and newly developed non-competitive Cleia. J. Hypertens. 41, e36 (2023).
doi: 10.1097/01.hjh.0000939192.01041.c0
Ono, Y. et al. Screening cutoff values for the detection of aldosterone-producing adenoma by LC-MS/MS and a novel noncompetitive CLEIA. J. Endocr. Soc. 8(6), bvae080 (2024).
doi: 10.1210/jendso/bvae080
Vorselaars, W. M. C. M., Valk, G. D., Vriens, M. R., Westerink, J. & Spiering, W. Case detection in primary aldosteronism: High-diagnostic value of the aldosterone-to-renin ratio when performed under standardized conditions. J. Hypertens. 36(7), 1585–1591 (2018).
doi: 10.1097/HJH.0000000000001718
Nishizaka, M. K., Pratt-Ubunama, M., Zaman, M. A., Cofield, S. & Calhoun, D. A. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension”. Am. J. Hypertens. 18(6), 805–812 (2005).
doi: 10.1016/j.amjhyper.2005.01.002
Calhoun, D. A., Nishizaka, M. K., Zaman, M. A., Thakkar, R. B. & Weissmann, P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6), 892–896 (2002).
doi: 10.1161/01.HYP.0000040261.30455.B6
Gomez-Sanchez, C. E. et al. Immunohistochemistry of the human adrenal CYP11B2 in normal individuals and in patients with primary aldosteronism. Horm. Metab. Res. 52(6), 421–426 (2020).
doi: 10.1055/a-1139-2079
Ward, G., Simpson, A., Boscato, L. & Hickman, P. E. The investigation of interferences in immunoassay. Clin. Biochem. 50(18), 1306–1311 (2017).
doi: 10.1016/j.clinbiochem.2017.08.015
Seiler, L. et al. Diagnosis of primary aldosteronism: Value of different screening parameters and influence of antihypertensive medication. Eur. J. Endocrinol. 150(3), 329–337 (2004).
doi: 10.1530/eje.0.1500329
Tuhan, H. U. et al. Cross-reactivity of adrenal steroids with aldosterone may prevent the accurate diagnosis of congenital adrenal hyperplasia. J. Pediatr. Endocrinol. Metab. 28(5–6), 701–704 (2015).